Product Certification&
    Enterprise Certification

  • Mr.simon
    Tel: 86-021-58380978

  • Mobile:13482386415
  • Tel:86-021-58380978
  • Fax:86-021-58380977
  • URL:http://www.systeambc.com
  • Province/state:shanghai
  • City:shanghai
  • Street:Building 87,Lane 669, Dong Jing Road Shanghai,P.R.China
  • MaxCard:
Home > Products >  Trelagliptin,SYR-472

Trelagliptin,SYR-472 CAS NO.865759-25-7

  • FOB Price: USD: 111.00-111.00 /Gram Get Latest Price
  • Min.Order: 100 Gram
  • Payment Terms: L/C
  • Available Specifications:

    ≥98.0%(100-1000)Gram≥98.0%(1000-5000)Gram

  • Product Details

Keywords

  • 865759-25-7
  • Trelagliptin,SYR-472
  • Trelagliptin;1-(2-broMo-5-fluorobenzyl)-6-chloro-3-MethylpriMidine-2,4(1H, 3H)-dione;Trelagliplin;(R)-2-[[6-(3-AMinopiperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl]Methyl]-4-fluoroben

Quick Details

  • ProName: Trelagliptin,SYR-472
  • CasNo: 865759-25-7
  • Molecular Formula: C18H20FN5O2
  • Appearance: white crystalline solid
  • Application: Active pharmaceutical ingredients. Tre...
  • DeliveryTime: 4weeks
  • PackAge: 100g,500g,1kg,25kg/drum
  • Port: shang hai
  • ProductionCapacity: 1000 Gram/Week
  • Purity: ≥98.0%
  • Storage: Dry seal
  • Transportation: shipping
  • LimitNum: 100 Gram

Superiority

We are specialized in custom synthesis, chemical/pharmaceutical/ pesticides outsourcing and contract research.
 
 
 
We are committed to provide excellence in researching, manufacturing and drug discovery process.
 
 
 
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.

 

Details

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
IC50 value:
Target: DPP4
Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog